Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Replimune Group, Inc. - Common Stock (NQ:REPL)

11.89 -0.03 (-0.25%)
Streaming Delayed Price Updated: 12:20 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Replimune Group, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
REPL SHAREHOLDER ALERT: Replimune Group Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
From Pomerantz LLP
Via GlobeNewswire
Top movers in Friday's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding... 
Via Benzinga
Top stock movements in today's session. ↗
Via Chartmill
Gapping stocks in Friday's session ↗
Via Chartmill
Friday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of... 
Via Benzinga
News headline image
Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
Advisory Committee voted 10 to 3 that the efficacy results from the IGNYTE study are evaluable and clinically meaningful 
From Replimune, Inc.
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into Replimune Group Inc. (REPL) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Replimune Group Inc. (REPL) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Replimune Group Inc. (REPL) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
These stocks are moving in today's session ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
Which stocks are gapping on Tuesday? ↗
Via Chartmill
Which stocks are moving before the opening bell on Tuesday? ↗
Via Chartmill
Thursday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
FDA decision expected by August 2, 2026 
From Replimune, Inc.
Via GlobeNewswire
News headline image
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s.... 
Via InvestorPlace
News headline image
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
From Replimune, Inc.
Via GlobeNewswire
Top stock movements in today's session. ↗
Via Chartmill
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
Top movers in Friday's pre-market session ↗
Via Chartmill
News headline image
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
From Replimune, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
From Pomerantz LLP
Via GlobeNewswire
News headline image
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.